- Home
- QH vs HLVX Comparison
QH vs HLVX Comparison
Compare QH & HLVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QH
- HLVX
- Stock Information
- Founded
- QH 2012
- HLVX 2020
- Country
- QH China
- HLVX United States
- Employees
- QH N/A
- HLVX N/A
- Industry
- QH Business Services
- HLVX Biotechnology: Pharmaceutical Preparations
- Sector
- QH Consumer Discretionary
- HLVX Health Care
- Exchange
- QH Nasdaq
- HLVX Nasdaq
- Market Cap
- QH 115.7M
- HLVX 105.2M
- IPO Year
- QH 2020
- HLVX 2022
- Fundamental
- Price
- QH $0.12
- HLVX $2.07
- Analyst Decision
- QH
- HLVX Hold
- Analyst Count
- QH 0
- HLVX 1
- Target Price
- QH N/A
- HLVX $2.00
- AVG Volume (30 Days)
- QH 18.4M
- HLVX 804.1K
- Earning Date
- QH 08-27-2025
- HLVX 08-06-2025
- Dividend Yield
- QH N/A
- HLVX N/A
- EPS Growth
- QH N/A
- HLVX N/A
- EPS
- QH 0.01
- HLVX N/A
- Revenue
- QH $417,431,053.00
- HLVX N/A
- Revenue This Year
- QH N/A
- HLVX N/A
- Revenue Next Year
- QH N/A
- HLVX N/A
- P/E Ratio
- QH $13.26
- HLVX N/A
- Revenue Growth
- QH N/A
- HLVX N/A
- 52 Week Low
- QH $0.09
- HLVX $1.34
- 52 Week High
- QH $2.27
- HLVX $2.17
- Technical
- Relative Strength Index (RSI)
- QH 22.24
- HLVX 50.24
- Support Level
- QH $0.09
- HLVX $2.07
- Resistance Level
- QH $0.14
- HLVX $2.10
- Average True Range (ATR)
- QH 0.11
- HLVX 0.06
- MACD
- QH -0.08
- HLVX -0.01
- Stochastic Oscillator
- QH 1.62
- HLVX 38.24
About QH Quhuo Limited American Depository Shares
Quhuo Ltd is a gig economy platform focusing on local life services in China. It provide tech-enabled, end-to-end operational solutions to consumer service businesses, including on-demand delivery solutions, mobility service solutions, housekeeping and accommodation solutions, and other services. Its three operating segments, include (i) on-demand delivery solutions, (ii) mobility service solutions, and (iii) housekeeping and accommodation solutions and other services.
About HLVX HilleVax Inc.
HilleVax Inc is a clinical-stage biopharmaceutical company. The company is focused on developing and commercializing novel vaccines. The firm's initial program, HIL-214, is a virus-like particle (VLP) based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection.